Please check your internet connection and try again.
# Tabvoihep (Hepatitis B Immune Globulin/Hepatitis B Vaccine Combination)
## Overview
Tabvoihep is a combination product containing Hepatitis B Immune Globulin (HBIG) and Hepatitis B Vaccine. It provides both passive (antibody) and active (vaccine-induced) immunity against the Hepatitis B virus (HBV).
## Primary Indications
* Prophylaxis against HBV infection in neonates born to HBsAg-positive mothers.
* Post-exposure prophylaxis following percutaneous or sexual exposure to HBV in individuals who have not been vaccinated or who are not adequately protected by vaccination.
## Adult Dosing
For neonates born to HBsAg-positive mothers:
Administer 0.5 mL intramuscularly (IM) within 12 hours of birth, ideally at the same time and in a different limb than the Hepatitis B vaccine.
For post-exposure prophylaxis (percutaneous or sexual exposure):
Dosing depends on the individual's vaccination status and the nature of the exposure. A common regimen for unvaccinated individuals after percutaneous exposure includes HBIG 0.06 mL/kg IM plus Hepatitis B vaccine. Follow specific post-exposure prophylaxis guidelines.
## Pediatric Dosing
For neonates born to HBsAg-positive mothers:
Administer 0.5 mL intramuscularly (IM) within 12 hours of birth.
## Dose Adjustments
No specific dose adjustments are routinely indicated for renal or hepatic impairment.
## Contraindications
* Known severe allergic reaction (anaphylaxis) to any component of the vaccine or HBIG, including thimerosal (if present).
* Individuals with a previous severe reaction to HBIG or Hepatitis B vaccine.
## Adverse Effects
Common adverse effects include injection site reactions (pain, redness, swelling), fever, headache, and fatigue. Less common but serious adverse effects include anaphylaxis and other hypersensitivity reactions.
## Key Drug Interactions
Concurrent administration with other immune globulins or vaccines requires careful consideration of timing and injection site. Consult specific guidelines for concomitant use.
## Monitoring
* Monitor for signs of hypersensitivity reactions following administration.
* For neonates, monitor HBsAg status and anti-HBs levels at 9-12 months of age to confirm immunity.
* For post-exposure prophylaxis, follow recommended serologic testing schedules.
## Clinical Pearls
* TabvoiheiP provides both immediate (passive) and long-term (active) protection.
* Ensure administration within the recommended timeframe after birth or exposure for optimal efficacy.
* Administer IM in the anterolateral thigh for neonates and infants, and in the deltoid muscle for older children and adults, if the gluteal muscle is used, care must be taken to avoid injury to the sciatic nerve.
* Dosing for post-exposure prophylaxis should be guided by current CDC or local public health guidelines.
***
*This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for the most current and complete drug information.*
